natgillin/translations-raw huggingface dataset:
VTE = Venous thromboembolic events which included DVT, PE, and death considered to be thromboembolic in origin * p value versus placebo = 0.0002 
VTE = venski trombembolični dogodki; obsegali so GVT, PE in smrt, za katero je bilo ocenjeno, da je posledica trombembolije * Vrednost p v primerjavi s placebom = 0,0002
Moderate and mild renal impairment 
Zmerna in blaga okvara ledvic
Arterial line injection 
Injiciranje v arterijsko linijo
INSTRUCTIONS FOR USE: PRE-FILLED SYRINGE 
NAVODILA ZA UPORABO: NAPOLNJENA INJEKCIJSKA BRIZGA
The safety and efficacy of enoxaparin sodium in children have not been established (see section 4.2). 
Varnost in učinkovitost natrijevega enoksaparinata pri otrocih nista ugotovljeni (glejte poglavje 4.2).
Inhixa should not be used interchangeably with other medicines belonging to the group of low molecular weight heparins. 
Zdravila Inhixa se ne sme uporabljati medsebojno zamenljivo z drugimi zdravili iz skupine nizkomolekularnih heparinov.
Enoxaparin sodium is administered by deep subcutaneous injection. 
Natrijev enoksaparinat se daje z globoko subkutano injekcijo.
Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerisation to lower molecular weight species with much reduced biological potency. 
Natrijev enoksaparinat se presnovi predvsem v jetrih z desulfuracijo in/ali depolimerizacijo v vrste z manjšo molekulsko maso in veliko manjšo biološko močjo.
Other medicines and Inhixa Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. 
Druga zdravila in zdravilo Inhixa Obvestite svojega zdravnika ali farmacevta, če uporabljate ali pa boste morda začeli uporabljati katero koli drugo zdravilo.
Signs of an allergic reaction include: rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue - if you are allergic to heparin or other low molecular weight heparins such as nadroparin, tinzaparin or dalteparin - if you have had a reaction to heparin that caused a severe drop in the number of your clotting cells (platelets) - this reaction is called heparin-induced thrombocytopenia - within the last 100 days or if you have antibodies against enoxaparin in your blood - if you are bleeding heavily or have a condition with a high risk of bleeding (such as stomach ulcer, recent surgery of the brain or eyes), including recent bleeding stroke - if you are using Inhixa to treat blood clots in your body and going to receive spinal or epidural anaesthesia or lumbar puncture within 24 hours - if the patient is a premature or newborn baby up to 1 month because of the risk of severe toxicity including abnormal respiration (“gasping syndrome”). 
Med znaki alergijske reakcije so: izpuščaj, težave s požiranjem ali dihanjem, oteklost ustnic, obraza, žrela ali jezika; - če ste alergični na heparin ali druge nizkomolekularne heparine, npr. na nadroparin, tinzaparin ali dalteparin; - če ste imeli v zadnjih 100 dneh reakcijo na heparin, ki je povzročila hudo zmanjšanje števila trombocitov (krvnih ploščic) - takšno reakcijo imenujemo s heparinom izzvana trombocitopenija - ali če imate v krvi protitelesa proti enoksaparinu; - če močno krvavite ali imate kakšno motnjo, ki jo spremlja veliko tveganje za krvavitev (npr. razjedo na želodcu, nedavno operacijo na možganih ali očeh), vključno z nedavno možgansko kapjo zaradi možganske krvavitve; - če uporabljate Inhixa za zdravljenje krvnih strdkov in imate v 24 urah predvideno spinalno anestezijo, epiduralno anestezijo ali lumbalno punkcijo; - če je pacient novorojenček ali prezgodaj rojen novorojenček do 1 meseca starosti zaradi tveganja za hudo toksičnost, vključno z nenormalnim dihanjem ("sindrom hlastanja za zrakom").
You will be given 2,000 IU (20 mg) or 4,000 IU (40 mg) of Inhixa each day. 
Dobili boste 2.000 i.e. (20 mg) ali 4.000 i.e. (40 mg) zdravila Inhixa na dan.
• Your doctor or nurse will normally give you Inhixa. 
• Običajno vam bo zdravilo Inhixa dal zdravnik ali medicinska sestra.
Pack-sizes of 1 or 5 vials containing 10 mL. 
Pakiranja s 1 ali 5 vialami, ki vsebujejo 10 ml.
All Treated Medical Patients During Acute Illness 
Vsi zdravljeni nekirurški bolniki med akutno boleznijo
Insert the full length of the needle into the skin fold. 
Celotno dolžino igle zabodite v kožno gubo.
However, your doctor may give you a further dose of 50 IU to 100 IU (0.5 to 1 mg) for every kilogram of your weight, if necessary. 
Vendar vam zdravnik lahko da dodaten odmerek od 50 do 100 i.e. (0,5 do 1 mg) na kilogram telesne mase, če je to potrebno.
Do not mix with other medicinal products. 
Zdravila ne smete mešati z drugimi zdravili.
• Inhixa is usually given by injection underneath the skin (subcutaneous). 
• Zdravilo Inhixa se po navadi injicira pod kožo (subkutano).
Enoxaparin sodium is to be used with extreme caution in patients with a history (> 100 days) of heparin-induced thrombocytopenia without circulating antibodies. 
Natrijev enoksaparinat je treba skrajno previdno uporabljati pri bolnikih z anamnezo (> 100 dni) heparinsko izzvane trombocitopenije brez protiteles v obtoku.
Pack-sizes of 1 vial containing 3 mL. 
Pakiranja z 1 vialo, ki vsebuje 3 ml.
The safety and efficacy of enoxaparin sodium in paediatric population have not been established. 
Varnost in učinkovitost natrijevega enoksaparinata pri pediatrični populaciji nista ugotovljeni.
The contents of the bag should be gently mixed. 
Vsebino vrečke nežno premešajte.
Patients received enoxaparin sodium (4,000 IU (40 mg) subcutaneously) daily for 6 to 10 days and were then randomly assigned to receive either enoxaparin sodium or placebo for another 21 days. 
Bolniki so prejemali natrijev enoksaparinat (4.000 i.e. (40 mg) subkutano) na dan od 6 do 10 dni, potem pa so bili randomizirani na prejemanje natrijevega enoksaparinata ali placeba za nadaljnjih 21 dni.
Pre-filled syringe 3 years 
Napolnjena injekcijska brizga 3 leti
See section “Do not use Inhixa”. 
Glejte tudi poglavje "Ne uporabljajte zdravila Inhixa".
• If you have restricted mobility due to illness, you will normally be given 4,000 IU (40 mg) of Inhixa each day. 
Če imate zaradi bolezni omejeno mobilnost, boste po navadi dobili 4.000 i.e. (40 mg) zdravila Inhixa na dan.
Treatment of unstable angina and NSTEMI 
Zdravljenje nestabilne angine pektoris in NSTEMI
Plasma anti-IIa activity after subcutaneous administration is approximately ten-fold lower than anti-Xa activity. 
Plazemska aktivnost anti-IIa je po subkutani uporabi približno desetkrat manjša kot aktivnost anti-Xa.
If you forget to use Inhixa 
Če ste pozabili uporabiti zdravilo Inhixa
• Acetylsalicylic acid (ASA), clopidogrel or other medicines used to stop blood clots from forming (see also section 3, “Changing of anticoagulant medicine”) 
• Acetilsalicilno kislino (ASA), klopidogrel ali druga zdravila, ki se uporabljajo za preprečevanje nastajanja krvnih strdkov (glejte tudi poglavje 3 "Menjava antikoagulantnih zdravil" ).
Enoxaparin sodium should be administered through an intravenous line. 
Natrijev enoksaparinat je treba dati po intravenski liniji.
Besides the anticoagulant effects of enoxaparin sodium, there was no evidence of adverse effects at 15 mg/kg/day in the 13-week subcutaneous toxicity studies both in rats and dogs and at 10 mg/kg/day in the 26-week subcutaneous and intravenous toxicity studies both in rats, and monkeys. 
Poleg antikoagulantnega učinka natrijevega enoksaparinata niso ugotovili znakov neželenih učinkov ne v 13-tedenski študiji toksičnosti subkutane uporabe 15 mg/kg/dan pri podganah in psih ne v 26-tedenskih študiji toksičnosti subkutane in intravenske uporabe 10 mg/kg/dan pri podganah in opicah.
All Treated Extended Prophylaxis Patients 
Vsi zdravljeni bolniki s podaljšano profilakso
If you stop using Inhixa 
Če ste prenehali uporabljati zdravilo Inhixa
See “Do not use Inhixa”. 
Glejte tudi "Ne uporabljajte zdravila Inhixa".
You will be given 2,000 IU (20 mg) or 
Dobili boste 2.000 i.e. (20 mg) ali
Because of the content of benzyl alcohol (see section 6.1), enoxaparin sodium multiple dose vial formulation must not be given to newborns or premature neonates (see sections 4.4 and 4.6). 
Zaradi vsebnosti benzilalkohola (glejte poglavje 6.1) se novorojenčkom ali prezgodaj rojenim novorojenčkom ne sme dajati formulacije večodmernih vial z natrijevim enoksaparinatom (glejte poglavji 4.4 in 4.6).
For treatment of acute STEMI in elderly patients ≥ 75 years of age, an initial intravenous bolus must not be used. 
Za zdravljenje akutnega STEMI pri starejših bolnikih, starih ≥ 75 let, se ne sme uporabiti začetnega intravenskega bolusa.
Solution for injection in pre-filled syringe. 
raztopina za injiciranje v napolnjeni injekcijski brizgi.
For intravenous injection, either the multidose vial or pre-filled syringe can be used. 
Za intravensko injiciranje je mogoče uporabiti ali večodmerno vialo ali napolnjeno injekcijsko brizgo.
Overall list of possible side effects: Very common ( may affect more than 1 in 10 people) 
Celotni seznam možnih neželenih učinkov: Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov):
Intravenous administration of benzyl alcohol has been associated with serious adverse events and death in neonates (“Gasping Syndrome”) (see section 4.3). 
Intravensko dajanje benzilalkohola je bilo povezano s hudimi neželenimi dogodki in smrtjo pri novorojenčkih (»sindrom hlastanja za zrakom«) (glejte poglavje 4.3).
These agents include medicinal products such as: - Systemic salicylates, acetylsalicylic acid at anti-inflammatory doses, and NSAIDs including ketorolac, - Other thrombolytics (e.g. alteplase, reteplase, streptokinase, tenecteplase, urokinase) and anticoagulants (see section 4.2). 
Med takšna zdravila spadajo na primer: - sistemski salicilati, acetilsalicilna kislina v protivnetnih odmerkih in NSAID, vključno s ketorolakom, - drugi trombolitiki (npr. alteplaza, reteplaza, streptokinaza, tenekteplaza, urokinaza) in antikoagulansi (glejte poglavje 4.2).
Investigations o Rare: Hyperkalaemia* (see sections 4.4 and 4.5). 
Preiskave o Redki: Hiperkaliemija* (glejte poglavji 4.4 in 4.5)
Your doctor will request you perform blood tests called INR and tell you when to start Inhixa accordingly. 
Zdravnik vam bo naročil, da opravite preiskavo krvi, imenovano INR, in vam bo glede na to povedal, kdaj naj nehate uporabljati zdravilo Inhixa.
Benzyl alcohol (see leaflet for further information) Water for injections 
Benzilalkohol (za več informacij glejte navodilo za uporabo).
Intracranial haemorrhage, Retroperitoneal haemorrhage 
Intrakranialna krvavitev, retroperitonealna krvavitev
• In patients with renal impairment, there is an increase in exposure of enoxaparin sodium which increases the risk of bleeding. 
• Bolniki z okvaro ledvic so bolj izpostavljeni natrijevemu enoksaparinatu in to povečuje tveganje za krvavitev.
Intravenous (bolus) injection (for acute STEMI indication only) For acute STEMI, treatment is to be initiated with a single intravenous bolus injection immediately followed by a subcutaneous injection. 
Intravensko (bolusno) injiciranje (samo za indikacijo akutni STEMI) Zdravljenje akutnega STEMI je treba začeti z eno intravensko bolusno injekcijo, ki ji neposredno sledi subkutana injekcija.
Pack-sizes of 5 vials containing 5 mL. 
Pakiranja s 5 vialami, ki vsebujejo 5 ml.
The 2 hours preoperative initiation of enoxaparin sodium 2,000 IU (20 mg) is not compatible with neuraxial anaesthesia. 
Dvourna predoperacijska uvedba 2.000 i.e. (20 mg) natrijevega enoksaparinata ni združljiva z nevraksialno anestezijo.
Patients receiving the twice daily doses (i.e. 75 IU/kg (0.75 mg/kg) twice daily or 100 IU/kg (1 mg/kg) twice-daily) should omit the second enoxaparin sodium dose to allow a sufficient delay before catheter placement or removal. 
Bolniki, ki prejemajo odmerke dvakrat na dan (tj. 75 i.e./kg (0,75 mg/kg) dvakrat na dan ali 100 i.e./kg (1 mg/kg) dvakrat na dan), morajo izpustiti drugi odmerek natrijevega enoksaparinata, da se zagotovi zadosten presledek med namestitvijo ali odstranitvijo katetra.
Spinal/Epidural anaesthesia or lumbar puncture 
Spinalna/epiduralna anestezija ali lumbalna punkcija
Percutaneous coronary revascularization procedures 
Postopki za perkutano koronarno revaskularizacijo
Intravenous (Bolus) Injection (for acute STEMI indication only) 
Intravensko (bolusno) injiciranje (samo za indikacijo akutni STEMI)
• you have liver problems 
• če imate težave z jetri
If a manual compression method is used, sheath should be removed 6 hours after the last intravenous/ subcutaneous enoxaparin sodium injection. 
Če uporabite ročno kompresijo, morate ovojnico odstraniti 6 ur po zadnji intravenski/subkutani injekciji natrijevega enoksaparinata.
As with other anticoagulants, haemorrhage may occur in the presence of associated risk factors such as: organic lesions liable to bleed, invasive procedures or the concomitant use of medicinal products affecting haemostasis (see sections 4.4 and 4.5). 
Tako kot pri drugih antikoagulansih se krvavitev lahko pojavi v prisotnosti spremljajočih dejavnikov tveganja, npr.: organskih lezij, nagnjenih h krvavitvi, invazivnih posegov ali sočasne uporabe zdravil, ki vplivajo na hemostazo (glejte poglavji 4.4 in 4.5).
Push hard the plunger. 
9) Močno stisnite bat.
#p value versus placebo = 0.537 
#Vrednost p v primerjavi s placebom = 0,537
What Inhixa contains - The active substance is enoxaparin sodium. 
Kaj vsebuje zdravilo Inhixa - Zdravilna učinkovina je natrijev enoksaparinat.
Medicinal products increasing potassium levels 
Zdravila, ki zvišujejo koncentracijo kalija
Do not use this medicine if you notice any change in the appearance of the product. 
Zdravila ne uporabite, če opazite spremembe v videzu raztopine.
• Your doctor will decide how much Inhixa to give you. 
• Zdravnik bo določil, koliko zdravila Inhixa boste dobili.
Solution for injection in multidose vial 1 vial 
Raztopina za injiciranje v večodmerni viali 1 viala
• If you have any sign of blockage of a blood vessel by a blood clot such as: - cramping pain, redness, warmth, or swelling in one of your legs - these are symptoms of deep vein thrombosis - breathlessness, chest pain, fainting or coughing up blood - these are symptoms of a pulmonary embolism 
• Če imate kakršen koli znak zamašitve žile s krvnim strdkom, na primer: - krčevite bolečine, pordelost, toploto ali oteklost ene noge - to so simptomi globoke venske tromboze, - težko dihanje, bolečino v prsih, omedlevico ali izkašljevanje krvi - to so simptomi pljučne embolije.
4,000 IU (40 mg) of Inhixa each day. 
4.000 i.e. (40 mg) zdravila Inhixa na dan.
Medicinal products affecting haemostasis (see section 4.4) It is recommended that some agents which affect haemostasis should be discontinued prior to enoxaparin sodium therapy unless strictly indicated. 
Zdravila, ki vplivajo na hemostazo (glejte poglavje 4.4) Pred začetkom zdravljenja z natrijevim enoksaparinatom je priporočljivo opustiti nekatera zdravila, ki vplivajo na hemostazo, če niso strogo indicirana.
Inhixa contains sodium 
Zdravilo Inhixa vsebuje natrij
o For patients with a high venous thromboembolism (VTE) risk who undergo abdominal or pelvic surgery for cancer an extended thromboprophylaxis up to 4 weeks is recommended. 
o Pri bolnikih z velikim tveganjem za vensko trombembolijo (VTE) s trebušno ali medenično operacijo zaradi raka je priporočljiva podaljšana tromboprofilaksa do 4 tedne.
How to use Inhixa 
Kako uporabljati zdravilo Inhixa
Enoxaparin sodium is a biological substance obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. 
Natrijev enoksaparinat je biološka snov, dobljena z alkalno depolimerizacijo heparinovega benzilestra, pridobljenega iz črevesne sluznice svinj.
Inhixa contains the active substance called enoxaparin sodium that is a low molecular weight heparin (LMWH). 
Zdravilo Inhixa vsebuje učinkovino natrijev enoksaparinat, ki je nizkomolekularni heparin (NMH).
Stopping blood clots forming in your blood in the following situations: Operation or periods of limited mobility due to an illness 
Ustavitev nastajanja krvnih strdkov v krvi v naslednjih okoliščinah: Ob operacijah ali obdobjih omejene mobilnosti zaradi bolezni Odmerek bo odvisen od verjetnosti, da se vam pojavi strdek.
Placebo once a day subcutaneously n (%) 
Placebo enkrat na dan subkutano n (%)
Carefully pull off the needle cap from the syringe. 
Z brizge previdno snemite pokrovček igle.
Your pre-filled syringe has UltraSafe Passive needle guard attached to it in order to protect you from needle stick injury. 
Vaša napolnjena injekcijska igla je opremljena s UltraSafe Passive spripomočkom za zaščito igle, ki služi za zaščito pred vbodom z iglo.
Benzyl alcohol (75 mg in 5.0 mL) 
Benzilalkohol (75 mg in 5,0 mL)
o For patients managed with PCI, if the last subcutaneous dose of enoxaparin sodium was given less than 8 hours before balloon inflation, no additional dosing is needed. 
o Če je bil pri bolnikih, zdravljenih s PKI, zadnji subkutani odmerek natrijevega enoksaparinata uporabljen manj kot 8 ur pred balonskim širjenjem, dodatno dajanje ni potrebno.
For dosage in elderly patients with impaired kidney function, see below “renal impairment” and section 4.4. 
Za odmerjanje pri starejših bolnikih z okvarjenim delovanjem ledvic glejte spodaj "Okvara ledvic" in poglavje 4.4.
Benzyl alcohol (150 mg in 10.0 mL) 
Benzilalkohol (150 mg in 10,0 ml)
System Organ Class 
Organ ski sistem
*p value versus placebo = 0.008 
*Vrednost p v primerjavi s placebom = 0,008
ATC code: B01A B05 
Farmakoterapevtska skupina: antitrombotiki, heparinska skupina, oznaka ATC: B01A B05
Additional bolus for PCI when last subcutaneous administration was given more than 8 hours before balloon inflation 
Dodaten bolus za PKI, če je bil zadnji subkutani odmerek uporabljen več kot 8 ur pred balonskim širjenjem
After repeated subcutaneous administration of 4,000 IU (40 mg) once daily and 150 IU/kg (1.5 mg/kg) once daily regimens in healthy volunteers, the steady-state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose. 
Po ponavljajoči se subkutani uporabi 4.000 i.e. (40 mg) enkrat na dan in 150 i.e./kg (1,5 mg/kg) enkrat na dan pri zdravih prostovoljcih je stanje dinamičnega ravnovesja doseženo 2. dan, povprečno razmerje izpostavljenosti pa je približno 15 % večje kot po enkratnem odmerku.
• Injection site nodules* (inflammatory nodules, which were not cystic enclosure of enoxaparin). 
• Vozliči* na mestu injiciranja (vnetni vozliči, ki niso bili cistični skupki enoksaparina).
Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection Inhixa 6,000 IU (60 mg)/0.6 mL solution for injection Inhixa 8,000 IU (80 mg)/0.8 mL solution for injection Inhixa 10,000 IU (100 mg)/1 mL solution for injection enoxaparin sodium 
Inhixa 2.000 i.e. (20 mg)/0,2 ml raztopina za injiciranje Inhixa 4,000 i.e. (40 mg)/0,4 mL raztopina za injiciranje Inhixa 6,000 i.e. (60 mg)/0,6 mL raztopina za injiciranje Inhixa 8,000 i.e. (80 mg)/0,8 mL raztopina za injiciranje Inhixa 10,000 i.e. (100 mg)/1 mL raztopina za injiciranje natrijev enoksaparinat
Excipient(s) with known effect 
Pomožna snov/pomožne snovi z znanim učinkom
Extended prophylaxis of DVT following cancer surgery A double-blind, multicentre trial, compared a four-week and a one-week regimen of enoxaparin sodium prophylaxis in terms of safety and efficacy in 332 patients undergoing elective surgery for abdominal or pelvic cancer. 
Podaljšana profilaksa GVT po onkoloških operacijah Dvojno slepo multicentrično preskušanje je primerjalo štiritedensko in enotedensko shemo profilakse z natrijevim enoksaparinatom glede varnosti in učinkovitosti pri 332 bolnikih, ki so imeli opravljeno elektivno operacijo zaradi raka v trebuhu ali medeničnem predelu.
Driving and using machines Inhixa does not affect the ability to drive and operate machinery. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Inhixa ne vpliva na sposobnost upravljanja vozil in strojev.
Benzyl alcohol (45 mg in 3.0 mL) 
Benzilalkohol (45 mg in 3,0 ml)
The use of a tuberculin syringe or equivalent is recommended when using multiple-dose vials to assure withdrawal of the appropriate volume of drug. 
Pri uporabi večodmernih vial je za odvzem ustrezne količine zdravila priporočljivo uporabiti tuberkulinsko ali drugo enakovredno brizgo.
Total VTE (%) 
Vse VTE (%)
• you are underweight or overweight 
• če imate premajhno ali preveliko telesno maso
• you have had a recent stroke 
• če ste nedavno imeli možgansko kap
Enoxaparin sodium pharmacokinetics appeared similar than control population, after a single 25 IU, 50 IU or 100 IU/kg (0.25, 0.50 or 1.0 mg/kg) intravenous dose however, AUC was two-fold higher than control. 
Farmakokinetika natrijevega enoksaparinata je bila po enkratnih intravenskih odmerkih 25 i.e., 50 i.e. ali 100 i.e./kg (0,25, 0,50 ali 1,0 mg/kg) podobna kot v kontrolni populaciji, toda AUC je bila dvakrat večja kot v kontrolni populaciji.
2) Stopping blood clots forming in your blood. 
2) Preprečuje nastanek krvnih strdkov v krvi.
Before injecting yourself with Inhixa 
Preden si injicirate zdravilo Inhixa
Extracorporeal use (in the dialysis circuit). 
Izventelesna uporaba (v dializnem obtoku).
Frequencies are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); and very rare (< 1/10,000) or not known (cannot be estimated from available data). 
Opredelitev pogostnosti je: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in zelo redki (< 1/10.000) ali neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov) Pri vsakem organskem sistemu so neželeni učinki navedeni po padajoči resnosti.
• Prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism (VTE). 
• Profilakso venske trombembolične bolezni pri nekirurških bolnikih z akutno boleznijo (npr. z akutnim srčnim popuščanjem, respiratorno insuficienco, hudimi okužbami ali revmatskimi boleznimi) in zmanjšano mobilnostjo, ki imajo povečano tveganje za vensko trombembolijo (VTE).
Therefore, for patients on enoxaparin sodium, the PCI was to be performed on enoxaparin sodium (no switch) using the regimen established in previous studies i.e. no additional dosing, if last subcutaneous administration given less than 8 hours before balloon inflation, intravenous bolus of 30 IU/ kg (0.3 mg/kg) enoxaparin sodium, if the last subcutaneous administration given more than 8 hours before balloon inflation. 
Zato je morala biti za bolnike na natrijevem enoksaparinatu PKI narejena na natrijevem enoksaparinatu (brez menjave) in po shemi, oblikovani v predhodnih študijah - tj. brez dodatnega odmerjanja, če je bila zadnja subkutana uporaba manj kot 8 ur pred balonskim širjenjem, in intravenski bolus 30 i.e./kg (0,3 mg/kg) natrijevega enoksaparinata, če je bila zadnja subkutana uporaba več kot 8 ur pred balonskim širjenjem.
• For acute STEMI, treatment is to be initiated with a single intravenous bolus injection immediately followed by a subcutaneous injection. 
• Zdravljenje akutnega STEMI je treba začeti z eno intravensko bolusno injekcijo, ki ji neposredno sledi subkutana injekcija.
• Uncommon: Hepatocellular liver injury* 
• Občasni: Hepatocelularna okvara jeter*
If the last subcutaneous administration was given more than 8 hours before balloon inflation, an intravenous bolus of 30 IU/kg (0.3 mg/kg) enoxaparin sodium should be administered. 
Če je bil zadnji subkutani odmerek uporabljen več kot 8 ur pred balonskim širjenjem, je treba dati intravenski bolus 30 i.e./kg (0,3 mg/kg) natrijevega enoksaparinata.
Overall list of possible side effects Very common (may affect more than 1 in 10 people) 
Celotni seznam možnih neželenih učinkov Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov):
After you have had a heart attack 
• če imate umetno srčno zaklopko
Supplied in packs of 1 and 5 vials. 
Pakirano v škatlah po 1 ali 5 vial.